H eart failure (HF) is a leading cause of morbidity and mortality, and despite optimal medical treatment, patients with NYHA class III-IV symptoms have a 2-year mortality rate approaching 50%. 1, 2 About half of the deaths from HF occur suddenly, 3, 4 and ventricular arrhythmias account for a large percentage of these sudden cardiac deaths (SCDs). 1 There is a strong correlation between chronic increased activity of the sympathetic nervous system (SNS) and poor prognosis in HF. [5] [6] [7] Interestingly, ␤-adrenergic receptor (␤AR) blockers that block the target receptors for catecholamines released during SNS activation reduce HF progression and arrhythmia vulnerability in patients with HF, leading to improved survival. 8, 9 Activation of the ␤AR signaling cascade driven by the SNS caused by HF initially results in a compensatory response aimed at enhancing cardiac contractility, but when SNS activation is sustained, maladaptive changes occur. 10 Chronic SNS activation desensitizes cardiac ␤AR signaling, 5 which further contributes to reduced inotropic reserve and worsens remodeling in HF, as part of a maladaptive response that ultimately fails to protect the heart or preserve cardiac function. 11
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Defective intracellular Ca 2ϩ homeostasis has been consistently reported in HF. 12, 13 Because intracellular Ca 2ϩ concentrations ([Ca 2ϩ ] i ) directly regulate contractility of cardiomyocytes, a reduced [Ca 2ϩ ] i transient amplitude in HF results in decreased force development. A prolonged decay of the [Ca 2ϩ ] i transient and increased diastolic [Ca 2ϩ ] i may contribute to slowed relaxation of the failing heart. [13] [14] [15] Several defects in the intracellular [Ca 2ϩ ] i metabolism have been reported, including depressed Ca 2ϩ uptake, storage, and/or release of Ca 2ϩ from the sarcoplasmic reticulum (SR) storage organelle. [15] [16] [17] Depressed SR Ca 2ϩ release may result from decreased SR Ca 2ϩ uptake via the SR Ca 2ϩ ATPase (SERCA2a), as well as a competitive increase of Ca 2ϩ extrusion to the extracellular space via upregulated function of the plasma membrane Na ϩ /Ca 2ϩ exchanger. 14, 18 Increased diastolic SR Ca 2ϩ leak may also result in decreased SR Ca 2ϩ loading and depressed contractility in HF. 19, 20 Diastolic SR Ca 2ϩ leak is caused by "leaky" ryanodine receptor (RyR2)/SR Ca 2ϩ release channels, which display an increased sensitivity to Ca 2ϩ -induced Ca 2ϩ release and incomplete channel closure during diastole in HF. 21 We 21-23 and others 24 -26 have previously demonstrated that chronic SNS hyperactivity in HF leads to increased protein kinase A (PKA) phosphorylation of RyR2 in the heart, which results in decreased binding of the channel-stabilizing subunit calstabin2 (FKBP12.6). 21 These findings highlight the important role of defects in RyR2 in HF as previously discussed in a Circulation editorial. 10 The role of leaky RyR2 and SNS activation in triggering ventricular arrhythmias is supported by the observation that inherited mutations in the RyR2 gene cause sudden cardiac death. 27, 28 Patients with catecholaminergic polymorphic ventricular tachycardia (CPVT) are heterozygous for the mutant RyR2 allele and are highly susceptible to exercise-induced cardiac arrhythmias. 29, 30 The new study by Oda and colleagues in this issue of Circulation expands the insights into the fundamental mechanisms of defective RyR2 function in HF and cardiac arrhythmias and suggests a role for defective interdomain interactions within RyR2 as a contributing factor in the development of an abnormal diastolic SR Ca 2ϩ leak. 31
Concept of Intramolecular Domain Unzipping
Missense mutations in the homologous RyR1 channel gene that have been linked to diseases of the skeletal muscle, including malignant hyperthermia (MH) and central core disease (CCD), cluster in regions of the RyR1 channel that correspond to the regions of the RyR2 channel that contain the CPVT mutations. We previously noted that similarity between the distribution of CPVT and MH/CCD mutations in RyR2 and RyR1, respectively, raises the possibility that similar biophysical defects in the cardiac and skeletal RyR channels account for CPVT and MH/CCD. 32 Indeed, the majority of MH mutations in RyR1 are located in welldefined domains of the RyR1 channel, also referred to as MH clusters or hot-spot regions. 32 Under experimental conditions, MH mutant RyR1 channels display a phenotype similar to CPVT mutations in RyR2, hyperactivity under resting conditions, and Ca 2ϩ leak from the SR into the cytoplasm. Ikemoto and colleagues have proposed that N-terminal and central domains in RyR1 contribute to the conformational stabilization of the closed state of the channel via domainzipping interactions. 33, 34 More simply put, they predict that sequences of the channel that are not adjacent to one another in the linear peptide sequence can interact once the channel is folded into its 3-dimensional structure. Furthermore, Ikemoto and colleagues have proposed that channel opening during excitation-contraction coupling requires domain unzipping to reduce the conformational energy constraints necessary to induce the open state. 34, 35 According to the domain-zipping model, MH-associated mutations occurring in either the N-terminal or central domains of RyR1 reduce the affinity of the zipper domains, resulting in leaky channels.
To test this hypothesis, a domain-specific peptide (DP4) corresponding to the putative RyR1 central zipper domain was applied to inhibit binding of the central to the N-terminal zipper domain. The resulting channel defects in RyR1 are similar to those observed in MH-associated RyR1 mutations (eg, increased channel open probability, abnormal SR Ca 2ϩ release, and hypersensitivity to activation). 33, 36, 37 A note of caution should be introduced, however, because experiments with synthetic peptides are susceptible to artifacts from unspecific peptide binding resulting from excess peptide concentrations. It was proposed that defective interdomain interactions within MH-mutant RyR1 channels contribute to leaky RyR1 channels that cause MH. 38
Defective Intermolecular Domain Interactions in the Cardiac RyR2 Isoform and Correlation With Structural Studies
Because skeletal RyR1 and cardiac RyR2 are 66% homologous at the protein level, it was proposed that domain unzipping may also occur in the cardiac Ca 2ϩ -release channel RyR2. Oda and colleagues have designed a synthetic peptide (DPc10), corresponding to Gly2460-Pro2495 of RyR2. Binding of the peptide DPc10 to the hypothetical N-terminal zipper domain of RyR2 was found to increase sensitivity to Ca 2ϩ -dependent channel activation and diastolic SR Ca 2ϩ leak to levels observed in failing hearts. In contrast, introduction of the CPVT-associated RyR2 mutation Arg2474Ser into DPc10 (DPc10-mut) abolished these effects indirectly, suggesting that the DPc10-mut peptide, which was not able to interfere with the interdomain interaction or to produce domain unzipping effects, may mimic effects of the identical CPVT mutation in the RyR2 channel, as we have shown earlier. 28 To further test the hypothesis that DPc10 produced unzipping of interacting N-terminal and central domains in RyR2, the fluorescent label MCA was cross-linked to RyR2 with DPc10 peptide targeting. Site-specific antibody labeling of calpain-digested RyR2 fragments revealed that MCA bound to the N-terminal 120 kDa of RyR2. These data support the idea that the N-terminal and central domains of RyR2 interact with each other. Interestingly, data from cryo-electron microscopy studies of RyR2 support this observation as well. 39 Serysheva and coworkers recently published the 3-dimensional RyR1 structure at 14 Å resolution, and projected residues 216 to 572 of the N-terminus within a group of structural surface domains that form the 4 corners of the cytoplasmic aspect of the channel tetramer, also referred to as the clamp regions (Figure, A and B) . These findings are consistent with previous localization studies of the RyR1 and RyR3 N-termini at significantly lower resolutions. 40, 41 Interestingly, the clamp structure containing the N-terminus projection was shown to undergo conformational changes corresponding to channel opening and closing 42, 43 and appears to be localized near the calstabin1 (FKBP12) binding region. 44 Because we and others have shown that calstabin1 (FKBP12) binds to the central domain of the full-length RyR1 involving the critical amino acid Val 2461 corresponding to Ile 2427 in the cardiac RyR2, 45, 46 the structural and experimental data provide further support for the concept of N-terminal and central domain interaction. Moreover, Wagenknecht and colleagues have demonstrated that Thr 1366 within divergent region 2 (DR2) localizes to clamp domain 6 in RyR1, 47 whereas 44 The central zipper domain corresponding to DPc10 is indicated in green and is proposed to interact with an as-yet undefined N-terminal zipper domain possibly corresponding to the projected clamp region sequence (pink). DR3 (orange) is shown in close proximity to the zipper and the calstabin2 binding domains. Alterations of N-terminal with central domain interactions by PKA RyR2 hyperphosphorylation, CPVT mutations, and/or calstabin2 depletion may destabilize the channel closed state and contribute to a diastolic SR Ca 2ϩ leak that promotes heart failure progression and/or triggers fatal cardiac arrhythmias. 21, 49 The figure is not drawn to scale. Reprinted with permission from Journal of Molecular Biology. 57 Copyright 2005, Elsevier.
Thr 1874 within DR3 localizes to clamp domain 9 near the calstabin binding region in RyR2 (Figure, B) . 48 Because of the high degree of sequence identity, it is likely that RyR1 intradomain mechanisms and interactions with calstabin1 similarly apply to the cardiac RyR2 and calstabin2, as summarized in part C of the Figure. It should be noted, however, that no direct structural evidence of interdomain interaction is available, although a casual observer of the RyR channel 3-dimensional structures will readily appreciate extensive domain interactions in the huge cytoplasmic domain of this largest of all ion channels (Figure, B) .
Further support for the hypothesis of interacting N-terminal and central domains within RyR2 was obtained with the bulky fluorescence quencher QSY-BSA. The rationale of peptide targeting of the MCA fluorescent probe to the N-terminus of RyR2 was used in combination with the large fluorescence quencher to monitor accessibility of unzipped domain configurations. Measurement of QSY-BSA fluorescence quenching was considerably increased after treatment with DPc10 or cAMP (which increases PKA phosphorylation of RyR2 at Ser 2809 ). 49 Confirming previous results, accessibility of the QSY-BSA quencher was also significantly increased in SR preparations from failing hearts, which is consistent with domain unzipping resulting from PKA hyperphosphorylation of RyR2. 21 Under physiological conditions, stress or exercise result in transiently increased PKA phosphorylation of RyR2 at Ser 2809 , which transiently decreases the binding affinity of calstabin2 to RyR2 and increases Ca 2ϩ -dependent activation of the channel. 28, 49, 50 Thus, after PKA phosphorylation of RyR2, there is increased SR Ca 2ϩ release for any given trigger [Ca 2ϩ ] i . 28, 50 On the other hand, chronic PKA hyperphosphorylation of RyR2 in HF results in incomplete channel closure during diastole, which causes depletion of the SR Ca 2ϩ store and reduced systolic Ca 2ϩ release. 19, 21, 51 Experiments with the QSY-BSA fluorescence quencher revealed that DPc10induced domain unzipping does not induce calstabin2 dissociation by itself. Rather, the observations by Oda et al suggest that unzipping may (1) facilitate PKA phosphorylation of RyR2 and (2) enhance calstabin2 dissociation in response to PKA phosphorylation of RyR2. These data suggest that peptide-induced domain unzipping would increase the accessibility of the PKA catalytic subunit (which is bound to RyR2 via the targeting protein mAKAP) to the PKA phosphorylation site Ser 2809 on RyR2. 52 Alternatively, under physiological conditions PKA phosphorylation may be expected to induce conformational changes in RyR2 consistent with domain unzipping. Determination of the exact role of domain unzipping in the gating mechanism and regulation of RyR2 will require further studies. Such studies may also reveal how conformational changes in RyR2 resulting from PKA phosphorylation and domain unzipping reduce calstabin2 (FKBP12.6) binding affinity to the channel complex.
Leaky RyR2 Channels as a Therapeutic
Target for Heart Failure
The study by Oda and colleagues provides additional confirmation that abnormal RyR2 channel function in failing hearts is caused by chronically increased levels of PKA phosphor-ylation of the channel resulting in dissociation of the calsta-bin2 (FKBP12.6) subunit, which is consistent with previous studies. 20, 21, [23] [24] [25] [26] [53] [54] [55] Moreover, it suggests that domain unzipping may contribute to RyR2 channel dysfunction in HF. Together, these findings provide further support for the concept that normalizing RyR2 channel function may represent a novel therapeutic approach for treating HF. Initial studies have associated normalization of RyR2 function with therapeutic benefits in a canine model of HF and in patients with HF treated with ␤-blockers. [22] [23] [24] It was shown that blockade of ␤AR reduced intracellular cAMP levels and decreased PKA hyperphosphorylation of RyR2, leading to normalization of RyR2 macromolecular complex stoichiometry (eg, increasing binding of calstabin2 to RyR2) and inhibition of the diastolic SR Ca 2ϩ leak via RyR2 in failing hearts. It is well known, however, that ␤-blocker treatment offers only partial protection from HF progression and SCD and may come with unacceptable side effects, including lethargy, impotence, depression, and failure to improve exercise tolerance. 56 In proof-of-principle studies we have shown that a mutant calstabin2 with a neutralized charge that is able to bind to PKA phosphorylated RyR2 rescues channel function in CPVT mutant and PKA hyperphosphorylated RyR2, providing direct evidence for the ability of enhanced calstabin2 binding to normalize defective RyR2 function. 28 Therefore, we have postulated that interventions that increase calstabin2 binding to RyR2 may fix the diastolic SR Ca 2ϩ leak and prevent HF progression and triggered cardiac arrhythmias. 21 On the basis of our initial studies that demonstrated leaky RyR2 in HF, Matsuzaki and colleagues showed that JTV-519, a 1,4-benzothiazepine derivative, slows the progression of canine HF by inhibiting RyR2 hyperactivity and intracellular Ca 2ϩ leak. 55 We have demonstrated that JTV-519 can effectively suppress ventricular arrhythmias in a genetic mouse model by rebinding calstabin2 to RyR2 50 and normalize CPVT mutant RyR2 channel function, 27 indicating that JTV-519 and its derivatives could constitute a novel class of drugs known as "calcium release channel stabilizers" for the treatment of heart failure and cardiac arrhythmias.
In the study by Oda et al, the DPc10 peptide, cAMP, or calstabin2 dissociation from RyR2 by FK506 increased QSY-BSA quenching, which could be inhibited by JTV-519. Moreover, SR Ca 2ϩ store depletion in DPc10-treated or failing cardiomyocytes could be reversed by JTV-519 treatment. These data clearly establish the beneficial effects of JTV-519 at the cellular level, which extends previous in vivo findings. The experiments suggest that JTV-519 may stabilize domain interactions in the zipped state, which could be used as a therapeutic strategy against HF and ventricular arrhythmias. Caution must be applied to proposals to use JTV-519 for patients because it is known to have potent human K ϩ channel-blocking activity, which can cause QT prolongation as well as L-type Ca 2ϩ channel-blocking activity (shown to be detrimental in HF patients). However, recently we have synthesized novel derivatives of JTV-519 that have reduced human ether-a-go-go-and L-type channel-blocking activity. These new compounds, known as calcium release channel stabilizers, have enhanced efficacy in terms of fixing the leak in RyR2 channel in HF and preventing exercise-induced arrhythmias in mice, raising the possibility that such compounds could be developed into therapeutics for patients.
